Interstitial Lung Disease News

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, according to a press release.

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with rheumatoid arthritis-associated interstitial lung disease, according to data published in The Lancet Rheumatology.

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new online educational resource.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Patients with rheumatoid arthritis who demonstrate consistent long-term elevation of inflammatory markers have an increased risk for interstitial lung disease, according to data published in Arthritis Research & Therapy.

Less than half of patients with sarcoidosis had been treated by the 1-year mark since being diagnosed with the condition, according to results published in CHEST.

Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.